OncoMatch/Clinical Trials/NCT06839066
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
Is NCT06839066 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including HLX43 DOSE 1 and HLX43 DOSE 2 for nasopharyngeal carcinoma (npc).
Treatment: HLX43 DOSE 1 · HLX43 DOSE 2 · HLX43 DOSE 3 — The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to second-line herapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Metastatic disease required
recurrent/metastatic nasopharyngeal carcinoma; at least one measurable lesion per RECIST v1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy
failed or are intolerant to at least two prior lines of chemotherapy (including at least one platinum-based regimen)
Must have received: platinum-based chemotherapy
including at least one platinum-based regimen
Must have received: anti-PD-1 therapy
failed or are intolerant to...PD-1/PD-L1 inhibitor therapy
Must have received: anti-PD-L1 therapy
failed or are intolerant to...PD-1/PD-L1 inhibitor therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify